Announcement • 11h
MiniMed Showcases MiniMed Flex And MiniMed Go At The American Diabetes Association Scientific Sessions MiniMed announced an overview of its upcoming presence at the American Diabetes Association's (ADA) Scientific Sessions in New Orleans June 5-8. The meeting marks MiniMed's first U.S. diabetes congress since becoming a standalone public company — and the first to feature its newest generation of technology designed to give people with diabetes more freedom every day. At ADA, MiniMed will showcase technology designed to reduce the daily burden of diabetes while delivering strong clinical outcomes. From advanced automation to smaller, more intuitive designs, the company continues to focus on one simple idea: to make every day a better day for people with diabetes. In addition to its latest innovations, MiniMed will present emerging clinical data demonstrating the real-world impact of its connected solutions, including the impact of its recently refreshed sensor portfolio.Attendees will also have hands-on opportunities to explore the highly anticipated MiniMed Flex™ system, a next-generation screenless, smartphone-controlled pump with real-time SmartGuard™ automation, and MiniMed Go™, the smart insulin pen system that remembers, reminds and recommends. Announcement • May 23
MiniMed Announces Consistent Glycemic Outcomes Across Sensors Integrated with MiniMed 780G System MiniMed, a global leader in diabetes technology, announced results from a new randomized crossover study demonstrating that glycemic outcomes for study participants were virtually identical when using the MiniMed 780G system with either the Simplera Sync sensor or Instinct sensor, made by Abbott. This data, published in Diabetes Technology & Therapeutics, reinforces that the automated insulin delivery (AID) algorithm, not the sensor, is the primary determinant of clinical outcomes. Instinct (N=24) Simplera Sync (N=24) Time in Range 79.1% 80.6% (70–180 mg/dL) HbA1c 6.7% 6.8% Mean Sensor Glucose 137.9 mg/dL 139.5 mg/dL Time in Auto Mode 90.0% 92.6%. Twenty-four adult participants with type 1 diabetes were randomized to use either the Simplera Sync or Instinct sensor for a six-week period, then crossed over to the alternate sensor for an additional six weeks. Each crossover period utilized a new insulin pump to eliminate algorithm memory carryover effects. Both sensors maintained strong Time in Range during the study period, exceeding international consensus targets for glycemic control as defined by the American Diabetes Association. No cases of diabetic ketoacidosis (DKA), severe hypoglycemia, or unanticipated device effects were reported during the study. These results build on preliminary real-world evidence on 4,364 U.S. users of the MiniMed 780G system with type 1 diabetes that showed individuals who transitioned from the Guardian 4 sensor to the Instinct sensor maintained consistently strong glycemic outcomes. An updated real-world analysis of over 20,000 U.S. users of the MiniMed 780G system living with diabetes showed consistent results, validating the algorithm's central role in driving results. Guardian 4 sensor Instinct sensor Guardian 4 sensor Instinct sensor w/Recommended Settings Overall Overall w/Recommended Settings Number of Individuals 20245 20245 8558 8558 Time in Range 74.8% 76.6% 78.7% 80.5% (70–180 mg/dL) GMI 6.9% 6.9% 6.8% 6.7% Time in Auto Mode 90.0% 94.9% 93.2% 97.5%. Announcement • Apr 30
Minimed Group, Inc. Announces Health Canada License for Simplera Sync Sensor, Type 2 Diabetes Indication with Minimed 780G System MiniMed Group, Inc. announced Health Canada has licensed new software for the MiniMed 780G system, marking a meaningful step forward in diabetes care for Canadians. With this authorization, the MiniMed 780G system now offers greater flexibility, combining Meal Detection technology, and SmartGuard, with both the Guardian 4 and Simplera Sync sensors. Additionally, the system is now compatible with Fiasp and indicated for adults 18 years and older with Type 2 diabetes. Simplera Sync is a disposable, all-in-one sensor that requires no fingersticks with SmartGuard, no overtape, and features a simple, two-step insertion process, introducing a more comfortable wear experience while reducing the daily burden of diabetes management. The MiniMed 780G system's adaptive algorithm automatically anticipates, adjusts, and corrects glucose levels every 5 minutes, 24/7 – working around the clock so users can focus on what matters. It's the only system featuring Meal Detection technology, which automatically detects rising glucose and adjusts insulin delivery to help keep levels in range – even when users occasionally miss a dose or underestimate carbs. The system uses a treat to target algorithm with flexible glucose targets as low as 5.5 mmol/L; combined with an adaptive approach, it more closely mimics glucose levels of someone not living with diabetes. Since its initial launch, the MiniMed 780G system has accumulated extensive clinical and real-world evidence across diverse populations around the world, demonstrating its ability to help many people with T1D enhance their glucose management, reaching over 80% time in range 1,2 when using optimal settings (active insulin time of two hours and 5.5 mmol/L target glucose), well above the international target of 70%. It is also the only system compatible with the world's first 7-day infusion set, reducing changes to once weekly and delivering 96% fewer injections than multiple daily injections. The Simplera Sync sensor will be available in Canada later this year. The MiniMed 780G system can be used with the Guardian 4 sensor. Fingersticks required in manual mode & to enter SmartGuard. If symptoms don't match alerts & readings, use a fingerstick. Refer to user guide. Pivotal trial participants spend avg of > 93% in SmartGuard. Data on file from CIP 321: Pivotal Trial (Age 14-75). N=152. 2020; 16 US sites. Participants in a clinical trial reported the sensor was smaller and lighter than other sensors they have used. Data on file: CIP330, N=243. TIR was reached using the optimal settings that are the combination of glucose target at 100 mg/dL (5.5 mmol/L) and Active Insulin Time (AIT) at 2 hours for at least 95% of the time. SmartGuard feature settings for each single patient must be defined by HCPs based on individual targets and specific needs. Refers to auto correct, which provides bolus assistance. As this is an automated bolus, no action is required, feature can be turned on and off. Meal Detection technology is a component of SmartGuard. Although Meal Detection Technology can help with missed bolus forgiveness, taking a bolus 15 – 20 minutes before a meal provides significant improvement in post-meal control. We recommend taking a meal bolus. Refers to SmartGuard feature. Individual results may vary. Some user interaction required. Data on file. As of April 15, 2025. Choudhary P, et al. Diabetes Technol Ther 2024; 26 (Suppl. 3): S32-S37. Matejko B, et al. Diabetes Care. 2022;45:2628–2635. 
